These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 24374141)

  • 1. Genetic variation in the two-pore domain potassium channel, TASK-1, may contribute to an atrial substrate for arrhythmogenesis.
    Liang B; Soka M; Christensen AH; Olesen MS; Larsen AP; Knop FK; Wang F; Nielsen JB; Andersen MN; Humphreys D; Mann SA; Huttner IG; Vandenberg JI; Svendsen JH; Haunsø S; Preiss T; Seebohm G; Olesen SP; Schmitt N; Fatkin D
    J Mol Cell Cardiol; 2014 Feb; 67():69-76. PubMed ID: 24374141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atrial fibrillation and heart failure-associated remodeling of two-pore-domain potassium (K
    Wiedmann F; Schulte JS; Gomes B; Zafeiriou MP; Ratte A; Rathjens F; Fehrmann E; Scholz B; Voigt N; Müller FU; Thomas D; Katus HA; Schmidt C
    Basic Res Cardiol; 2018 Jun; 113(4):27. PubMed ID: 29881975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The two-pore domain potassium channel, TWIK-1, has a role in the regulation of heart rate and atrial size.
    Christensen AH; Chatelain FC; Huttner IG; Olesen MS; Soka M; Feliciangeli S; Horvat C; Santiago CF; Vandenberg JI; Schmitt N; Olesen SP; Lesage F; Fatkin D
    J Mol Cell Cardiol; 2016 Aug; 97():24-35. PubMed ID: 27103460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic Ablation of TASK-1 (Tandem of P Domains in a Weak Inward Rectifying K
    Schmidt C; Wiedmann F; Beyersdorf C; Zhao Z; El-Battrawy I; Lan H; Szabo G; Li X; Lang S; Korkmaz-Icöz S; Rapti K; Jungmann A; Ratte A; Müller OJ; Karck M; Seemann G; Akin I; Borggrefe M; Zhou XB; Katus HA; Thomas D
    Circ Arrhythm Electrophysiol; 2019 Sep; 12(9):e007465. PubMed ID: 31514528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. pH-dependent inhibition of K₂P3.1 prolongs atrial refractoriness in whole hearts.
    Skarsfeldt MA; Jepps TA; Bomholtz SH; Abildgaard L; Sørensen US; Gregers E; Svendsen JH; Diness JG; Grunnet M; Schmitt N; Olesen SP; Bentzen BH
    Pflugers Arch; 2016 Apr; 468(4):643-54. PubMed ID: 26729267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model.
    Wiedmann F; Beyersdorf C; Zhou X; Büscher A; Kraft M; Nietfeld J; Walz TP; Unger LA; Loewe A; Schmack B; Ruhparwar A; Karck M; Thomas D; Borggrefe M; Seemann G; Katus HA; Schmidt C
    J Am Heart Assoc; 2020 May; 9(10):e015751. PubMed ID: 32390491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cloning, functional characterization, and remodeling of K2P3.1 (TASK-1) potassium channels in a porcine model of atrial fibrillation and heart failure.
    Schmidt C; Wiedmann F; Langer C; Tristram F; Anand P; Wenzel W; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
    Heart Rhythm; 2014 Oct; 11(10):1798-805. PubMed ID: 24952150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TASK-1 and TASK-3 may form heterodimers in human atrial cardiomyocytes.
    Rinné S; Kiper AK; Schlichthörl G; Dittmann S; Netter MF; Limberg SH; Silbernagel N; Zuzarte M; Moosdorf R; Wulf H; Schulze-Bahr E; Rolfes C; Decher N
    J Mol Cell Cardiol; 2015 Apr; 81():71-80. PubMed ID: 25655935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac expression and atrial fibrillation-associated remodeling of K₂p2.1 (TREK-1) K⁺ channels in a porcine model.
    Schmidt C; Wiedmann F; Tristram F; Anand P; Wenzel W; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
    Life Sci; 2014 Mar; 97(2):107-15. PubMed ID: 24345461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the A293 (AVE1231) Binding Site in the Cardiac Two-Pore-Domain Potassium Channel TASK-1: a Common Low Affinity Antiarrhythmic Drug Binding Site.
    Wiedmann F; Kiper AK; Bedoya M; Ratte A; Rinné S; Kraft M; Waibel M; Anad P; Wenzel W; González W; Katus HA; Decher N; Schmidt C
    Cell Physiol Biochem; 2019; 52(5):1223-1235. PubMed ID: 31001961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel KCND3 gain-of-function mutation associated with early-onset of persistent lone atrial fibrillation.
    Olesen MS; Refsgaard L; Holst AG; Larsen AP; Grubb S; Haunsø S; Svendsen JH; Olesen SP; Schmitt N; Calloe K
    Cardiovasc Res; 2013 Jun; 98(3):488-95. PubMed ID: 23400760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy.
    Schmidt C; Wiedmann F; Zhou XB; Heijman J; Voigt N; Ratte A; Lang S; Kallenberger SM; Campana C; Weymann A; De Simone R; Szabo G; Ruhparwar A; Kallenbach K; Karck M; Ehrlich JR; Baczkó I; Borggrefe M; Ravens U; Dobrev D; Katus HA; Thomas D
    Eur Heart J; 2017 Jun; 38(22):1764-1774. PubMed ID: 28057773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNAs Regulate TASK-1 and Are Linked to Myocardial Dilatation in Atrial Fibrillation.
    Wiedmann F; Kraft M; Kallenberger S; Büscher A; Paasche A; Blochberger PL; Seeger T; Jávorszky N; Warnecke G; Arif R; Kremer J; Karck M; Frey N; Schmidt C
    J Am Heart Assoc; 2022 Apr; 11(7):e023472. PubMed ID: 35301863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cardiac two-pore-domain potassium channels (K2P): Physiology, pharmacology, and therapeutic potential].
    Schmidt C; Wiedmann F; Schweizer PA; Katus HA; Thomas D
    Dtsch Med Wochenschr; 2012 Aug; 137(33):1654-8. PubMed ID: 22875694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TASK-1 current is inhibited by phosphorylation during human and canine chronic atrial fibrillation.
    Harleton E; Besana A; Chandra P; Danilo P; Rosen TS; Rosen MR; Argenziano M; Robinson RB; Feinmark SJ
    Am J Physiol Heart Circ Physiol; 2015 Jan; 308(2):H126-34. PubMed ID: 25437921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept.
    Schmidt C; Wiedmann F; Schweizer PA; Katus HA; Thomas D
    Eur J Pharmacol; 2014 Sep; 738():250-5. PubMed ID: 24927994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stretch-activated two-pore-domain (K
    Schmidt C; Wiedmann F; Kallenberger SM; Ratte A; Schulte JS; Scholz B; Müller FU; Voigt N; Zafeiriou MP; Ehrlich JR; Tochtermann U; Veres G; Ruhparwar A; Karck M; Katus HA; Thomas D
    Prog Biophys Mol Biol; 2017 Nov; 130(Pt B):233-243. PubMed ID: 28526353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of cardiac two-pore-domain K+ (K2P) channels by the antiarrhythmic drug vernakalant--comparison with flecainide.
    Seyler C; Li J; Schweizer PA; Katus HA; Thomas D
    Eur J Pharmacol; 2014 Feb; 724():51-7. PubMed ID: 24374008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vernakalant activates human cardiac K(2P)17.1 background K(+) channels.
    Seyler C; Schweizer PA; Zitron E; Katus HA; Thomas D
    Biochem Biophys Res Commun; 2014 Aug; 451(3):415-20. PubMed ID: 25108155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TASK-1 channels may modulate action potential duration of human atrial cardiomyocytes.
    Limberg SH; Netter MF; Rolfes C; Rinné S; Schlichthörl G; Zuzarte M; Vassiliou T; Moosdorf R; Wulf H; Daut J; Sachse FB; Decher N
    Cell Physiol Biochem; 2011; 28(4):613-24. PubMed ID: 22178873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.